香港糖尿病生物样本库2型糖尿病研究发现:非白蛋白尿型糖尿病肾脏病与全因死亡及心血管和肾脏结局风险
香港糖尿病生物样本库纳入19,025例中国2型糖尿病患者,按基线eGFR和白蛋白尿分为四种DKD表型,比较多重结局风险。中位随访54,260人年期间,eGFR下降而无白蛋白尿亚组的全因死亡、心衰住院和CKD进展风险均高于无DKD组,但心血管疾病风险无显著升高。
要点
- 非白蛋白尿型DKD(eGFR下降无白蛋白尿)患者心衰住院和CKD进展风险显著高于无DKD者。
- 该亚组全因死亡风险亦显著升高(HR 1.59),但心血管疾病风险无显著差异(HR 1.14)。
- 白蛋白尿伴或不伴eGFR下降者,死亡、心血管疾病、心衰住院和CKD进展风险均升高。
核心结论
- 非白蛋白尿型DKD与较高的心衰住院和CKD进展风险相关,无论基线eGFR水平如何。
研究设计与样本
- 多中心前瞻性队列研究,纳入香港糖尿病生物样本库19,025例中国2型糖尿病成人患者。
主要发现
- 平均年龄61.1岁,男性占58.3%,平均糖尿病病程11.1年;随访54,260人年期间发生438例死亡、1,076例心血管疾病事件、298例心衰住院和1,161例CKD进展。
- 与无DKD亚组相比,eGFR下降无白蛋白尿亚组的全因死亡风险升高(HR 1.59,95%CI 1.04-2.44),心衰住院风险升高(HR 3.08,95%CI 1.82-5.21),CKD进展风险升高(HR 2.37,95%CI 1.63-3.43)。
- eGFR下降无白蛋白尿亚组的心血管疾病风险与无DKD亚组相比无显著差异(HR 1.14,95%CI 0.88-1.48)。
- 白蛋白尿伴或不伴eGFR下降者,死亡、心血管疾病、心衰住院和CKD进展风险均较高。
- 排除基线eGFR<30 mL/min/1.73 m2参与者的敏感性分析结果相似。
关键数值与推荐
- DKD表型按基线eGFR和白蛋白尿定义:无DKD(eGFR未下降且无白蛋白尿)、白蛋白尿无eGFR下降、eGFR下降无白蛋白尿、白蛋白尿伴eGFR下降。
- CKD进展定义为新发肾衰竭或持续性eGFR下降≥40%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 因药物使用可能导致潜在误分类。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Nonalbuminuric diabetic kidney disease (DKD) has become the prevailing DKD phenotype. We compared the risks of adverse outcomes among patients with this phenotype compared with other DKD phenotypes. STUDY DESIGN: Multicenter prospective cohort study. SETTINGS & PARTICIPANTS: 19,025 Chinese adults with type 2 diabetes enrolled in the Hong Kong Diabetes Biobank. EXPOSURES: DKD phenotypes defined by baseline estimated glomerular filtration rate (eGFR) and albuminuria: no DKD (no decreased eGFR or albuminuria), albuminuria without decreased eGFR, decreased eGFR without albuminuria, and albuminuria with decreased eGFR. OUTCOMES: All-cause mortality, cardiovascular disease (CVD) events, hospitalization for heart failure (HF), and chronic kidney disease (CKD) progression (incident kidney failure or sustained eGFR reduction ≥40%). ANALYTICAL APPROACH: Multivariable Cox proportional or cause-specific hazards models to estimate the relative risks of death, CVD, hospitalization for HF, and CKD progression. Multiple imputation was used for missing covariates. RESULTS: Mean participant age was 61.1 years, 58.3% were male, and mean diabetes duration was 11.1 years. During 54,260 person-years of follow-up, 438 deaths, 1,076 CVD events, 298 hospitalizations for HF, and 1,161 episodes of CKD progression occurred. Compared with the no-DKD subgroup, the subgroup with decreased eGFR without albuminuria had higher risks of all-cause mortality (hazard ratio [HR], 1.59 [95% CI, 1.04-2.44]), hospitalization for HF (HR, 3.08 [95% CI, 1.82-5.21]), and CKD progression (HR, 2.37 [95% CI, 1.63-3.43]), but the risk of CVD was not significantly greater (HR, 1.14 [95% CI, 0.88-1.48]). The risks of death, CVD, hospitalization for HF, and CKD progression were higher in the setting of albuminuria with or without decreased eGFR. A sensitivity analysis that excluded participants with baseline eGFR <30 mL/min/1.73 m2 yielded similar findings. LIMITATIONS: Potential misclassification because of drug use. CONCLUSIONS: Nonalbuminuric DKD was associated with higher risks of hospitalization for HF and of CKD progression than no DKD, regardless of baseline eGFR.
引用
- Jin Q, Luk AO, Lau ESH, et al. Nonalbuminuric Diabetic Kidney Disease and Risk of All-Cause Mortality and Cardiovascular and Kidney Outcomes in Type 2 Diabetes: Findings From the Hong Kong Diabetes Biobank. Am J Kidney Dis. 2022. PMID: 34999159. doi:10.1053/j.ajkd.2021.11.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。